Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone for Microalbuminuria in T2DM
NCT00500955Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2000
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Albumin:Creatinine Ratio at 32 weeks. Started Apr 2000; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00500955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500955.